Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;25 Suppl 1(Suppl 1):e14109.
doi: 10.1111/tid.14109. Epub 2023 Jul 29.

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy

Gemma Reynolds  1   2   3 , Victoria G Hall  1   2 , Benjamin W Teh  1   2
Affiliations
Review

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy

Gemma Reynolds et al. Transpl Infect Dis. 2023 Nov.

Abstract

Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with hematological malignancy. Revaccination post-cellular therapies are less well defined. This review highlights important considerations around poor vaccine response, seroprevalence preservation after cellular therapies, and the optimal timing of revaccination. Future research should assess the immunogenicity and real-world effectiveness of new vaccine formulations and/or vaccine schedules in patients post-HCT and cellular therapy, including analysis of vaccine response that relates to the target of cellular therapies.

Keywords: CAR-T cell; bispecific; cellular therapy; hematologic malignancy; stem cell transplant; vaccination.

PubMed Disclaimer

Conflict of interest statement

Victoria G. Hall and Gemma Reynolds have no conflicts of interest. Benjamin W. Teh has been on the advisory board for Moderna, CSL‐Behring, and Takeda. He has also received research funding from Merck Sharp and Dohme, Sanofi, and Seqirus.

Figures

FIGURE 1
FIGURE 1
Future approaches to vaccine research for hematopoietic cell transplant (HCT) and cellular therapies patients.
See this image and copyright information in PMC

References

    1. Niederwieser D, Baldomero H, Atsuta Y, et al. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT). Blood. 2019;134(suppl_1):2035. doi:10.1182/blood-2019-125232 - DOI
    1. Aljurf M, Weisdorf D, Alfraih F, et al. Worldwide network for blood & marrow transplantation (WBMT) special article, challenges facing emerging alternate donor registries. Bone Marrow Transplant. 2019;54(8):1179‐1188. doi:10.1038/s41409-019-0476-6 - DOI - PMC - PubMed
    1. Mackall C. How CAR‐T cells became the hot rods of cancer therapy. Nature. 2023;613. Accessed April 6th, 2023. https://www.nature.com/articles/d41586-023-00177-z
    1. Baird JH, Epstein DJ, Tamaresis JS, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B‐cell lymphoma. Blood Adv. 2021;5(1):143‐155. doi:10.1182/bloodadvances.2020002732 - DOI - PMC - PubMed
    1. Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123‐133. doi:10.1001/jama.2019.9053 - DOI - PMC - PubMed